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Abstract Live kidney donors are exhaustively screened
pre-donation, creating a cohort inherently healthier at
baseline than the general population. In recent years, three
renowned research groups reported unfavourable outcomes
for live kidney donors post-donation that contradicted their
previous studies. Here, we compared the study design and
analysis of the most recent and previous studies to deter-
mine whether the different outcomes were due to
methodological design or reflect a real potential disad-
vantage for living kidney donors. All six studies on long-
term risk after live kidney donation were thoroughly
screened for the selection of study population, controls,
data quality, and statistical analysis. Our detailed review of
the methodology revealed key differences with respect to
selection of donors and compared non-donors, data quality,
follow-up duration, and statistical analysis. In all studies,
the comparison group of non-donors was healthier than the
donors due to more extensive exclusion criteria for non-
donors. Five of the studies used both restriction and
matching to address potential confounding. Different
matching strategies and statistical analyses were used in the
more recent studies compared to previous studies and
follow-up was longer. Recently published papers still face
bias. Strong points compared to initial analyses are the
extended follow-up time, large sample sizes and better
analysis, hence increasing the reliability to estimate
potential risks for living kidney donors on the long-term.
Future studies should focus on equal selection criteria for
donors and non-donors, and in the analysis, follow-up
duration, matched sets, and low absolute risks among
donors should be accounted for when choosing the statis-
tical technique.
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Introduction
Live donor kidney transplantation is the treatment of
choice for patients with end-stage renal disease (ESRD).
The benefits of this treatment include pre-emptive trans-
plantation, superior organ quality, and increased graft
survival [1] and have led to an increase in live kidney
donations and consecutive transplants. Despite this
increase, the growing demand for donor kidneys cannot be
matched, which has led to an increase in the number of
extended-criteria live donors with minor comorbidities,
such as well-regulated hypertension or higher body mass
index (BMI) [2]. As a result, more than 20,000 transplants
from live kidney donors are performed annually world-
wide, and this number has remained stable over the past
decade [3, 4].
Live kidney donors are individuals who willingly
undergo major surgery to improve the well-being of
someone else. It is of the utmost importance to minimize
risks, such as the intra-operative risk of bleeding [5, 6]
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and mortality [7], and maximize donor safety during and
after donation as well as in the long-term. Live kidney
donors are exhaustively screened by a multidisciplinary
team of transplant professionals and anaesthesiologists
prior to donation, resulting in a cohort that is inherently
healthier at baseline than the general population.
Therefore, selecting non-donors with baseline health
similar to accepted donors is difficult and may affect
estimates of any potential risks attributable to donation.
In addition to the problem of adequate selection, an
extended follow-up period for live kidney donors is
important for revealing the risks of donation on their
long-term health [8, 9].
Three renowned research groups recently uncovered
unfavourable outcomes for live kidney donors following
donation compared to non-donors, including an increased
risk of cardiovascular and overall mortality [8], increased
risk of ESRD [8, 9], and increased risk of gestational
hypertension and preeclampsia [10]. The number of
events and absolute risks are low. Previous publications
from these research groups [Oslo University Hospital,
Johns Hopkins Medical Institutions, and the Donor
Nephrectomy Outcomes Research (DONOR) Network]
did not demonstrate unfavourable outcomes detrimental to
live kidney donors, as they reported a lower risk of long-
term cardiovascular [11] and overall mortality [11–13]
and lower risk of cardiovascular events [13]. This is
remarkable because studies from the same research group
largely included the same donor population. We compared
the study design and analysis of the three most recent
studies and the previous studies from the same research
groups.
Materials and methods
Literature search
We searched for studies that reported negative outcomes
following live kidney donation using MEDLINE, Embase,
CENTRAL (the Cochrane Library 2013), OvidSP, and
Google Scholar.
Literature screening
We selected studies published in the last 5 years with an
impact factor [15 or high citation rate [20. We found
three studies by three different research groups [8–10].
Previously, studies from these research groups reported
favourable outcomes following live kidney donation
[11–13] in the same donor cohort. The discrepancies in
outcomes of these studies have been highly debated within
the transplant community.
Outcome
In light of the impact of these studies on the transplant
community, we compared the methodology used in the
studies and the likely impact on outcomes. The six studies
were thoroughly screened by two authors (SJ and JNMI) in
regard to the selection of the study population, data quality,
and statistical analysis.
Results
Outcome and selection of study population
The Norwegian studies by Mjoen et al. were published in
2012 [11] and 2014 [8] and report on a single centre
experience with contradictory results (Table 1). They
studied a consecutive cohort of 2269 donors who donated
between 1963 and 2007 at a single centre in Oslo, Norway,
where all kidney transplantations in Norway are performed.
However, there were important differences in the selection
and comparability of donors and non-donors (Tables 2, 3).
In the 2014 study, 368 donors were excluded based on anti-
hypertensive medication, blood pressure[140/90 mmHg,
BMI[ 30 kg/m2, age [70 years or \20 years, macroal-
buminuria, or eGFR\ 70 ml/min per 1.73 m2. This
selection left only the healthiest donors. In the 2012 study,
comparison data on non-donors were obtained from the
Norwegian background population as provided by Statis-
tics Norway. The 2014 study derived the comparison group
from a Norwegian population-based cohort study (Helse-
undersøkelsene i Nord-Trøndelag, HUNT 1) carried out
between 1984 and 1987 [14]. However, data on kidney
function was not available for non-donors, while donors
with low renal function were excluded from the analysis.
Though similar donor and non-donor groups were studied,
the other two research groups from the US and Canada
reported on different outcomes, including long-term mor-
tality [12], ESRD [9], death and major cardiovascular
events [13], and gestational hypertension and preeclampsia
[10]. The previous US analysis selected a donor cohort
from the mandated national Organ Procurement and
Transplantation Network (OPTN) registry. A total of
80,347 donors between 1994 and 2009 with a median
follow-up of 6.3 years (maximum 12 years) were included
in this study, excluding 36 donors for whom age was not
recorded or were\18 years old. For the more recent US
analysis the selection period was extended to 2011,
increasing the donor cohort by 15,870 donors to a total of
96,217 donors with a median follow-up of 7.6 years
(maximum 15 years). Both studies derived their compar-
ison group of non-donors from National Health and
Nutrition Examination Survey (NHANES) III participants
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[12]. NHANES participants were matched 1:1 to live
donors with replacement to a predetermined maximum
permissible radius. If information on the live donor’s BMI
or systolic blood pressure was not available, a match was
selected with healthy BMI (20–30 kg/m2) or systolic blood
pressure (100–140 mmHg). Sampling with replacement
was performed when a matched participant was the only fit
despite ideal and radius matching. In the 2012 Canadian
analysis, a donor cohort was selected from live kidney
donors who donated between 1992 and 2009 in Ontario,
Canada, and were permanent residents of Ontario [13]. The
2015 study included female live kidney donors who
Table 1 Results of studies comparing live kidney donors to non-donors
Study Year Average follow-
up, years
Outcome Risk for
donor
Overall results, donors versus non-donors p value
Mjoen et al.
[11]
2012 14.7 Overall mortality ; – \0.001
Cardiovascular mortality ; – 0.004
Mjoen et al.
[8]
2014 15.1 All cause death : HR 1.30 (95 % CI 1.11–1.52) 0.001
Cardiovascular death : HR 1.40 (95 % CI 1.03–1.91) 0.030
End-stage renal disease : 302 cases per million; HR 11.38 (95 % CI
4.37–29.6)
0.001
Segev et al.
[12]
2010 6.3 Long-term mortality ; 1.5 versus 2.9 % 0.001
Muzaale
et al. [9]
2014 7.6 End-stage renal disease : 30.8 per 10,000 (95 % CI 24.3–38.5) versus
3.9 per 10,000 (95 % CI 0.8–8.9)
0.001
Garg et al.
[13]
2012 6.8 Death or major
cardiovascular event
; 2.8 versus 4.1 events per 1000 person years;
HR 0.66 (95 % CI 0.48–0.90)
0.010
Major cardiovascular event ; 1.7 versus 2.0 events per 1000 person years;
HR 0.85 (95 % CI 0.57–1.27)
–
Garg et al.
[10]
2015 11.0 Gestational hypertension
and preeclampsia
: 11 versus 5 %; OR 2.4 (95 % CI 1.2–5.0) 0.010
HR hazard ratio, CI confidence interval, OR odds ratio
Table 2 Selection of live kidney donors and non-donors
Study Year Donors
(n)
Donor
participation
(%)
Data collection Non-
donors
(n)
Derived from Average
follow-
up, years
Data collection
Mjoen
et al.
[11]
2012 2269 100 Norwegian Living Donor
registry
6807 Norwegian
background
population
n.a. Statistics Norway
database
Mjoen
et al.
[8]
2014 1901 84 Norwegian Living Donor
registry, Statistics Norway,
Norwegian Renal Registry
32,621 HUNT 1
1984-1987
24.9 Survey database,
Statistics Norway
database, Norwegian
Renal Registry
Segev
et al.
[12]
2010 80,347 100 OPTN registry, Social Security
Death Master File
80,347 NHANES III 12.0 Survey database, Social
Security Death Master
File
Muzaale
et al.
[9]
2014 96,217 100 OPTN registry, CMS, deceased
waitlist
96,217 NHANES III 15.0 Survey database, CMS
Garg
et al.
[13]
2012 2028 100 Medical records, Trillium
database, CIHI-DAD, OHIP
database, RPDB
20,280 General
Canadian
population
6.4 CIHI-DAD, OHIP
database, RPDB
Garg
et al.
[10]
2015 85 97 Medical records, Trillium
database, CIHI-DAD, OHIP
database, RPDB
510 General
Canadian
population
10.9 CIHI-DAD, OHIP
database, RPDB
OPTN Organ Procurement and Transplantation Network, CMS Centers for Medicare and Medicaid Services, CIHI-DAD Canadian Institute for
Health Information Discharge Abstract Database, OHIP Ontario Health Insurance Plan, RPDB Ontario Registered Persons Database
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donated a kidney between July 1, 1992, and April 30, 2010,
and who had at least one pregnancy with a gestation of at
least 20 weeks during follow-up. The study population
comprised only 88 donors. The non-donor comparison
group for both studies was derived from the adult general
population of Ontario in the Ontario Registered Persons
Database, which contains demographic and vital status
information for all Ontario residents. The starting date for
follow-up was the date of nephrectomy and assigned as the
index date. The donor index dates were randomly assigned
to all adult residents of Ontario. Residents were excluded if
any medical conditions that could preclude donation were
known. For the 2015 study, in addition to previous
restrictions depicted in Table 3, women with a previous
diagnosis of gestational hypertension or preeclampsia were
excluded from the analysis. Furthermore, the index data
was extended to ±2 years to account for era effects. Each
non-donor could be selected only once, resulting in
380,955 potential female non-donors (52 % of the original
sample), though matched sets could be found for only 85
donors.
Data quality
Data for donors and non-donors were collected from pre-
existing registries or databases (Table 2). Data were col-
lected prospectively in national registries for live kidney
donors in Norway, the US, and Ontario. In addition, the
Table 3 Comparability of live kidney donors to non-donors
Study Year Matched by Statistics
Mjoen
et al. [11]
2012 Restriction: Not performed Kaplan Meier analysis
Matching: 1:3 on age, gender, and year of birth
Mjoen
et al. [8]
2014 Restriction: Only inclusion of donors with a blood pressure B140/90 mmHg, BMI B30 kg/
m2, no antihypertensive medication, age 20–70 years, no macroalbuminuria, and eGFR
[69 ml/min per 1.73 m2. Only inclusion of non-donors with a blood pressure B140/90
mmHg, BMI B30 kg/m2, no diabetes or cardiovascular disease, no use of antihypertensive
medication, and if participants rated their own health as ‘‘good’’ or ‘‘excellent’’
Multiple imputation
Coarsed exact matching
Matching: on age, gender, year of inclusion, blood pressure, BMI, smoking Cox regression
Segev et al.
[12]
2010 Restriction of non-donors: Recorded kidney disease, diabetes, heart disease, and
hypertension, and who had missing data on any of the four aforementioned criteria were
excluded. The excluded participants also included those who answered positively to survey
questions regarding ‘‘if doctors had told them that they had’’ heart disease, lupus, cancer,
kidney stones or (pre)diabetes; difficulty independently performing physical activities or
chest/leg pain while performing physical activities; or no health insurance because of poor
health, illness, or age
Kaplan Meier analysis
Log-rank test between
group analysis
Matching: 1:1 with replacement on gender, ethnicity, and history of cigarette smoking, and
radius matching was done on age at donation, educational background, pre-operative BMI,
and pre-operative systolic blood pressure
Muzaale
et al. [9]
2014 Restriction: No change in design Kaplan Meier analysis
Log-rank test within group
analysis
Matching: No change in design Bootstrap methods
between group analysis
Garg et al.
[13]
2012 Restriction of non-donors: Evidence of diagnostic, procedural, or visit codes for
genitourinary disease, diabetes, hypertension, cancer, cardiovascular disease, pulmonary
disease, liver disease, rheumatological conditions, or chronic infections, a history of
nephrology consultation, evidence of frequent physician visits (more than four visits in the
previous two years), or any person who failed to see a physician at least once in the two
years before the index date
Log-rank test
Matching: 1:10 fashion on age (within two years), sex, index date (within six months), rural
(population less than 10,000) or urban residence, and income (categorized into fifths of
average neighbourhood income on the index date)
Cox regression
Garg et al.
[10]
2015 Restriction: Only inclusion of donors who had at least one pregnancy with a gestation of at
least 20 weeks during follow-up. No change in design for non-donors.
Generalized linear mixed
model
Matching: 1:6 fashion on age (within 2 years), sex, index date (within ±2 years), rural
(population less than 10,000) or urban residence, and income (categorized into fifths of
average neighbourhood income on the index date), the number of pregnancies carried to at
least 20 weeks of gestation before index date (0, 1, or C2), and the time to the first birth
after the index date
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Canadian studies verified the donor data from Ontario’s
central organ and tissue donation agency, the Trillium Gift
of Life, with donor medical records from five major
transplant centres. The Canadian studies did not state if
there was any discrepancy between the donor registry and
medical records. The outcomes were derived from reg-
istries in all six studies (Table 2). The Norwegian and
Canadian studies, as well as the first US study in 2010,
linked both the donor and non-donor data with the reg-
istries containing their studied outcomes. All outcomes
were specifically coded within the registries. The recent US
study in 2014 identified the outcome of ESRD differently
for donors and non-donors, potentially leading to infor-
mation bias. ESRD was defined as the initiation of main-
tenance dialysis, receipt of a living or deceased donor
kidney transplant, or placement on the deceased waiting
list. The outcome was ascertained by linkage to medical
evidence Form 2728 for the Centers for Medicare and
Medicaid Services (CMS). Donors were also linked to the
transplant network’s kidney waiting list.
Statistical analysis
All studies used both restriction and matching to address
potential confounding except for the 2012 analysis by
Mjoen et al. [11] (Table 3). The Norwegian research group
added restriction and altered their matching method for
their 2014 study. Mjoen et al. used Kaplan–Meier analysis
without adjustment of confounders in 2012. In 2014, Mjoen
et al. [8]. reported 31 ESRD events in 9 donors and 22
in non-donors. A majority of the donors who developed
ESRD were immediate family members of the recipient.
The Cox regression analyses for all outcomes including
ESRD were adjusted for six confounders: age, gender, year
of inclusion, blood pressure, BMI, and smoking. A second
adjusted model was created after multiple imputation of
blood pressure, BMI, and smoking. This latter model was
used for the primary analyses. In contrast, the US and
Canadian research groups did not alter the restriction and
matching methods for their recent analyses. Although all
outcomes were reported differently, as percentages, hazard
ratios, or odds ratios depending on the statistical methods
used. The US research group performed a Kaplan–Meier
analysis in both studies but used a bootstrap method to
properly estimate the variance of repeated sampling of non-
donors in their most recent study [9]. The crude incidence
of ESRD was 9 out of 1901 donors and 17 out of 32,621
non-donors, resulting in 36 cases of ESRD in the non-
donor group after matching with replacement. Persons aged
C65 years, African Americans, and Mexican Americans
had an increased risk of ESRD, whereas Caucasian non-
donors had no risk of ESRD. In the 2012 study by the
Canadian research group [13], differences in baseline
characteristics between donors and non-donors were
assessed using standardized differences. If these differ-
ences were [10 % they would reflect a meaningful
imbalance. A two-sided log-rank test stratified on matched
sets was used to compare differences in death and cardio-
vascular outcomes between donors and non-donors. Fur-
thermore, a Cox regression stratified on matched sets was
used to estimate hazard ratios with 95 % confidence
intervals. In the 2015 study by Garg et al. [10], generalized
linear models with generalized linear estimating equations
were used to compare the characteristics of donors and
non-donors at the index date, and generalized linear mixed
models with a random intercept and random effects logistic
regression models were used to compare pregnancy char-
acteristics and outcomes. These methods account for the
correlation structure within matched sets and in women
with more than one pregnancy during follow-up.
Discussion
Our detailed review of the methodology of the different
studies on long-term risk after live kidney donation
revealed key differences with respect to the comparability
of donors and non-donors in regard to selection, data
quality, follow-up, and statistical analysis (Table 4).
Selection of the study population
Donors are a pre-screened healthy selection of the popula-
tion. This is a key issue to account for when selecting the
comparison group of non-donors. Furthermore, the extended
donor selection criteria during the past decade [2] complicate
restriction rules when including non-donors. Both Norwe-
gian studies are a good example of choosing a more appro-
priate comparison group when studying the same donor
population. In the 2012 study by Mjoen et al. [11], the full
Norwegian background population was a comparison group
without restriction according to the live kidney donor
selection criteria. Therefore, the risk attributable to donation
could be underestimated despite matching 1:3 on age, gen-
der, and year of birth to account for confounding. In their
2014 study, Mjoen et al. [8], used the healthiest donors from
the earlier study. In addition, more healthy non-donors were
derived from a Norwegian population-based cohort study
[14]. The restriction rules for donors and non-donors did not
entirely lead to a match on renal function, cardiovascular
disease, and subjective perception of health, leading to the
possible overestimation of risk detrimental to donors
because of healthier non-donors.
The US studies used more extensive restriction rules and
matching for NHANES III participants compared to the
healthier donors. NHANES III participants were derived
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from 81 counties in the US based on geography and the
proportions of minority populations using probability pro-
portionate to size sampling. Young children, persons aged
C65 years, African Americans, and Mexican Americans
were subgroups that were oversampled and were not rep-
resentative of the donor population, the majority of which
is Caucasian (75 %). Both studies used a similar restriction
and matching strategy. The entire NHANES III cohort
comprised 20,024 adult participants. The excluded group
(n = 10,660) also contained participants who would be
eligible for living donation, presumably making the non-
donor group somewhat healthier than the donor population.
The 9364 eligible NHANES III participants were signifi-
cantly younger, more educated, had a higher proportion of
women and Caucasians, and had a lower proportion of
smokers than the donor population. This difference may
have led to an overestimation of risk attributable to dona-
tion, which was however not demonstrated in the study by
Segev et al.. The 2014 study by Mjoen et al. did demon-
strated an increased mortality risk for donors. In the more
recent US study, the strict selection of healthier non-donors
made them less likely to develop ESRD. The donor pop-
ulation had significantly higher systolic blood pressure,
BMI, and fraction of smokers at baseline, which are all
factors associated with an increased risk of ESRD [15].
Thus, the risk attributable to donation was likely overes-
timated. In a recent study by Grams et al. [16], a proportion
of the same aforementioned US donor population consist-
ing of 52,998 live kidney donors was analysed based on
their 15-year projected risk of ESRD, which was previ-
ously reported by Muzaale et al. [9]. In this recent study,
the risk of ESRD among live kidney donors was compared
to a meta-analysis of 4,933,314 participants in seven gen-
eral population cohorts who would be eligible for living
kidney donation according to 10 demographic and health
characteristics. The average follow-up for these cohorts
was 6.4 years and their 15-year risk projections for ESRD
were compared among US live kidney donors. The donors
had a 3.5–5.3-times higher projected 15-year risk than non-
donors. As pointed out by Steiner [17], the previous US
study by Muzaale et al. [9] reported an 8-times higher
incidence of ESRD among donors than non-donors. This
finding supports the notion that the risk attributable to
donation was overestimated in that study.
Both Canadian studies used a similar restriction and
matching strategy. The extended live donor eligibility cri-
teria over the years have caused the broad exclusion criteria
to encompass participants who would be eligible for living
donation, making the non-donor group healthier. Further-
more, any person who failed to see a physician at least once
in the 2 years before the index date was not included in the
analysis in order to ensure that everyone who was included
in the analysis had access to health care. This restriction
could have led to the exclusion of the healthiest non-donors
who did not require any medical attention in the past years
and who would be highly eligible for living donation.
Nevertheless, this exclusion criterion of healthier non-
donors in the Garg et al. [10] study had no effect on the
study results in a sensitivity analysis.
Data quality
The strength of the data collection in all studies was that
all data were collected mostly from national prospective
registries. The Canadian studies even verified donor data
with the donors’ medical records. However, there were
some limitations in the data collection in regard to donor
and non-donor medical outcomes and missing additional
information on outcomes. Donors could be more aware of
their health than non-donors, leading to differential mis-
classification because all outcomes except for death could
have been registered earlier. This could have led to more
registered outcomes among donors and an overestimated
risk attributable to donation. Non-donor data from the
population-based studies included data from surveys,
giving a subjective rating of HUNT 1 and NHANES III
Table 4 Overview of bias in selection of study population, data quality, and statistical analysis
Study Year Selection bias Risk of donation Information bias Risk of
donation
Confounding Risk of
donation
Donors Non-
donors
Donors Non-
donors
Mjoen et al. [11] 2012 - ? Underestimation ? - Overestimation - n/a
Mjoen et al. [8] 2014 ? ? Overestimation ? ? Overestimation ? Overestimation
Segev et al. [12] 2010 - ? Unclear ? ? Overestimation - n/a
Muzaale et al. [9] 2014 - ? Overestimation ? ? Overestimation ? Overestimation
Garg et al. [13] 2012 - ? Underestimation ? - Overestimation - n/a
Garg et al. [10] 2015 - ? No effect ? - Overestimation - n/a
? or – bias present/not present in study
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participants’ health. These non-donor data were not veri-
fied with medical records, but were used for restriction,
which could have led to an underestimation of risk among
non-donors. The 2014 US study prioritized live kidney
donors who developed ESRD on the deceased donor
transplant waiting list [18]. Pre-emptively placing live
kidney donors on the deceased waiting list possibly
resulted in more registered donors with ESRD. This was
seen in the higher crude incidence of ESRD among
donors (99 out of 96,217) compared to non-donors (crude
incidence 17 out of 9364). Non-donors who registered
pre-emptively on the deceased waiting list were not
identified as having ESRD, which caused a delay in the
registration of ESRD for non-donors. However, their
follow-up was longer than that of donors, and most non-
donors would either receive a transplant or initiate dialysis
shortly thereafter. Errors in the estimation of outcomes
occurred in donors who emigrated; given the large sample
sizes in both US studies, this is accepted to have had no
material effect on the outcomes of the studies. Moreover,
it will not affect the other studies given the high donor
participation.
In the Garg et al. 2012 study, data on blood pressure is
lacking [19], though previously the same authors demon-
strated an increase in blood pressure [20], which increases
the risk of cardiovascular events and mortality [21]. Lely
et al. [22] pointed out that the severity and gestational age
at which preeclampsia and gestational hypertension were
diagnosed was not provided in Garg et al.’s 2015 study.
Given that the rate of premature birth was not increased,
only mild or at-term preeclampsia likely occurred [22].
Although there is an increased risk of preeclampsia and
gestational hypertension in donors, the absolute risk is low
and the severity of the complications, such as premature
birth, are less than expected from a gynaecological point of
view.
Follow-up and statistical analysis
Differences between donors and non-donors in regard to
comparability and follow-up should be accounted for
during the analysis to overcome confounding. Restriction
and matching is the first step, but matched sets and
comparability should also be taken into consideration
during the analysis. In Mjoen et al.’s 2014 study, the
starting date of the follow-up for donors occurred decades
earlier, causing an increased duration of follow-up, as
pointed out by Boudville et al. [23], leading to a maxi-
mum follow-up time of 43.9 years for donors compared to
a maximum of 24.9 years for non-donors. Boudville et al.
suggested that secular changes in individuals’ health and
health care made the baseline characteristics not fully
comparable between the groups and could have resulted in
a higher incidence of ESRD among donors. The authors
tried to correct for this bias by adjusting for year of
inclusion. Furthermore, Boudville et al. [23]. raised some
concerns about statistical overfitting of the models used.
For Cox proportional hazard models, a rule of thumb is to
have at least 10 events per added confounder [24]. For the
outcome ESRD, there were 31 reported events, but the
primary analysis adjusted for six confounders. Both fac-
tors could have led to an overestimated risk attributable to
donation. Furthermore, what stands out in the baseline
characteristics of the donors and non-donors before any
matching or adjustments were performed, as pointed out
by Kaplan et al. [25], was the mean age difference of
46.0 ± 11.5 versus 37.6 ± 11.7 years, respectively. The
higher age of donors could have been a plausible expla-
nation for their increased risk of mortality. The Norwe-
gian authors later replied that this difference was
corrected by using coarsened exact matching in the sur-
vival analysis, which created strata of the potential con-
founders: age, gender, year of inclusion, blood pressure,
BMI, and smoking. Donors and non-donors were matched
based on these strata, after which the analysis was per-
formed on non-coarsened data. After this matching the
mean age of donors and non-donors was 46.0 versus
45.7 years, respectively [26]. For both US studies,
Matuchansky [27] pointed out that a different NHANES
cohort should have been selected instead of the partici-
pants from NHANES III; they proposed that participants
in the ‘‘continuous NHANES’’ cohort beyond 1994, up to
2006, would have been a better chronological fit for their
study cohort [27]. The US authors replied that the strength
of NHANES III lies in its larger sample size, greater
number of geographic areas, and availability of mortality
linkage beyond 10 years. Furthermore, a limitation of
‘‘continuous NHANES’’ is that it cannot be used for
survival comparisons [27, 28]. By using their specific
bootstrap, the authors stated that this technique does not
lead to bias, and differences in follow-up were accounted
for by their use of survival analysis [29]. As pointed out
by Gill et al. [30], in an editorial accompanying the study
by Muzaale et al. [9], the crude incidence of ESRD was
extremely low for NHANES participants: 17 out of 9364.
Taken together with the longer follow-up of non-donors,
replacement of non-donors with long event-free survival
in matched analysis may have underestimated the risk of
ESRD in non-donors [30]. The matching technique was
also discussed by Matas et al. [15], who stated that
matching with replacement could magnify any differences
between donors and non-donors [15]. Furthermore, how
many times each control was used was not stated. The
authors replied that this technique has been established
and that a specifically designed bootstrap was created to
estimate the variance [31].
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Future perspectives
Live kidney donors are individuals who are not patients
themselves, and submitting them to a surgical procedure
stretches the Hippocratic oath taken by physicians.
Although the absolute risks for donors following donation
are very low, increased risks seem to exist among live
kidney donors compared to non-donors. Risks both during
and after donation are taken for granted by live kidney
donors to help patients with ESRD [32]. Reduced risk of
life-time dialysis, improved quality of life, and prolonged
survival are gained by the recipients [1]. Furthermore,
transplantation is far more cost-effective than dialysis
[33, 34]. Nevertheless, these benefits for kidney transplant
recipients should not outweigh the risks for live donors
after donation. Therefore, future studies should focus on
long-term outcomes following donation in which the risks
for donors are taken into consideration against the risks for
comparable non-donors.
Conclusions
We conclude that recently published papers still face bias that
could have led to a potential overestimation of risk
attributable to donation. Even if risks are elevated among live
kidney donors compared to non-donors, the absolute risks for
donors following donation are very low and should therefore
not discourage potential donors. Strong points of recent
analyses compared to initial analyses are the extended time of
follow up after donation, large sample sizes and better anal-
ysis, hence increasing the reliability to estimate potential risks
for living kidney donors on the long-term. Key problems
remain suchas that donors are a pre-screenedhealthy selection
of the general population, making it difficult to find an equal
healthy unscreened comparison group. Specifically, not all
required clinically relevant data are available for potential
comparison groups. Selecting a healthier comparison group
overestimates the risk attributable to donation. Future studies
should focus on equal inclusion criteria for donors and non-
donors, and in the analysis, follow-up duration, matched sets,
and low absolute risks among donors should be accounted for
when choosing the statistical technique. Ideally, long-term
outcomes should uncover risk estimates for potential donors
and how these risks would change if an individual becomes a
live kidney donor.
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